Fulcrum Therapeutics Has Received Written Notice From Bristol Myers Squibb-Acquired MyoKardia To End Their Collaboration And License Agreement, Originally Signed On July 20, 2020, The Termination Will Officially Take Effect On June 26, 2025-8K

Fulcrum Therapeutics已收到來自百時美施貴寶收購的MyoKardia的書面通知，結束兩者於2020年7月20日簽訂的合作與許可協議，終止將在2025年6月26日正式生效-8K

Benzinga · 03/05 11:46

Under this agreement, Fulcrum had granted MyoKardia exclusive rights to develop products targeting specific genes linked to certain genetic heart conditions.
Until the termination of the agreement, the parties will continue to perform their respective obligations under the agreement. As of the termination date, the agreement will be terminated in its entirety, following which Fulcrum will not be entitled to receive any further milestone payments, royalties, or research activity cost reimbursement.
Under the agreement, pursuant to a mutually agreed research plan, Fulcrum agreed to perform assay screening and related research activities to identify and validate up to a specified number of potential cardiomyopathy gene targets for further research, development, manufacture and commercialization by MyoKardia.
Under the agreement, MyoKardia made a $10.0 million upfront payment and a $2.5 million payment as prepaid research funding to Fulcrum. MyoKardia also agreed to reimburse Fulcrum for the costs of the research activities not covered by the prepaid research funding, up to a maximum amount of total research funding (including the prepaid research funding). Upon the achievement of specified milestones, Fulcrum would have been entitled to preclinical milestone payments, development milestone payments and sales-based milestone payments of up to $298.5 million in the aggregate per target for certain identified targets, and of up to $150.0 million in the aggregate per target for certain other identified targets. Fulcrum achieved a $2.5 million specified preclinical milestone. MyoKardia also agreed to pay Fulcrum tiered royalties ranging from a mid single-digit percentage to a low double-digit percentage based on MyoKardia's, and any of its affiliates' and sublicensees', annual worldwide net sales of products under the agreement directed against any identified target. The royalties were payable on a product-by-product basis during a specified royalty term, and could have been reduced in specified circumstances.

Under this agreement, Fulcrum had granted MyoKardia exclusive rights to develop products targeting specific genes linked to certain genetic heart conditions.
Until the termination of the agreement, the parties will continue to perform their respective obligations under the agreement. As of the termination date, the agreement will be terminated in its entirety, following which Fulcrum will not be entitled to receive any further milestone payments, royalties, or research activity cost reimbursement.
Under the agreement, pursuant to a mutually agreed research plan, Fulcrum agreed to perform assay screening and related research activities to identify and validate up to a specified number of potential cardiomyopathy gene targets for further research, development, manufacture and commercialization by MyoKardia.
Under the agreement, MyoKardia made a $10.0 million upfront payment and a $2.5 million payment as prepaid research funding to Fulcrum. MyoKardia also agreed to reimburse Fulcrum for the costs of the research activities not covered by the prepaid research funding, up to a maximum amount of total research funding (including the prepaid research funding). Upon the achievement of specified milestones, Fulcrum would have been entitled to preclinical milestone payments, development milestone payments and sales-based milestone payments of up to $298.5 million in the aggregate per target for certain identified targets, and of up to $150.0 million in the aggregate per target for certain other identified targets. Fulcrum achieved a $2.5 million specified preclinical milestone. MyoKardia also agreed to pay Fulcrum tiered royalties ranging from a mid single-digit percentage to a low double-digit percentage based on MyoKardia's, and any of its affiliates' and sublicensees', annual worldwide net sales of products under the agreement directed against any identified target. The royalties were payable on a product-by-product basis during a specified royalty term, and could have been reduced in specified circumstances.

根據該協議，Fulcrum 授予 MyoKardia 開發針對特定基因的產品的獨佔權，這些基因與某些遺傳性心臟病相關。
在協議終止之前，各方將繼續履行協議下的各自義務。到終止日期，協議將全部終止，之後Fulcrum將不再有權獲得任何進一步的里程碑付款、特許權使用費或研究活動費用的報銷。
根據協議，根據雙方約定的研究計劃，Fulcrum同意執行檢測篩查和相關研究活動，以識別和驗證最多指定數量的潛在心肌病基因靶點，以便MyoKardia進一步研究、開發、生產和商業化。
根據協議，MyoKardia 向 Fulcrum 支付了1000萬元的預付款和250萬元的預先研究資金。MyoKardia 還同意補償 Fulcrum 預先研究資金未覆蓋的研究活動費用，最高可達總研究資金（包括預先研究資金）。在達到特定里程碑時，Fulcrum 將有權獲得臨牀前里程碑付款、開發里程碑付款和基於銷售的里程碑付款，總額可達29850萬元，針對某些特定目標，以及針對其他一些特定目標，總額可達15000萬元。Fulcrum 達到了250萬元的特定臨牀前里程碑。MyoKardia 還同意根據 MyoKardia 及其任何附屬公司和許可方針對任何特定目標的產品的年度全球淨銷售額，向 Fulcrum 支付從中等單數百分比到低雙數百分比不等的分層特許權使用費。這些特許權使用費是在特定的特許權使用費期限內按產品逐個支付的，並且在特定情況下可以減少。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。

讚好

熱點推薦

搶先評論

Fulcrum Therapeutics Has Received Written Notice From Bristol Myers Squibb-Acquired MyoKardia To End Their Collaboration And License Agreement, Originally Signed On July 20, 2020, The Termination Will Officially Take Effect On June 26, 2025-8K

Fulcrum Therapeutics Has Received Written Notice From Bristol Myers Squibb-Acquired MyoKardia To End Their Collaboration And License Agreement, Originally Signed On July 20, 2020, The Termination Will Officially Take Effect On June 26, 2025-8K

風險及免責聲明

聲明